Pii to Manufacture FDA-Approved Breast Cancer Drug
September 23, 2019
Pii is now responsible for commercial drug product production of fulvestrant, a breast cancer drug, while Sagent Pharmaceuticals, its abbreviated new drug application holder, will sell, market, and distribute the drug product in the United States.